TABLE 2.
Univariate analysis of factors associated with negative treatment outcomes of bedaquiline-based multidrug-resistant tuberculosis therapies
| Negative outcome | Positive outcome | OR (95% CI) | p-value | |
| Patients | 15 | 37 | ||
| Lineage | ||||
| L2 | 8 (53.3) | 20 (48.6) | Reference | |
| L4 | 7 (46.7) | 17 (51.4) | 1.03 (0.31–3.43) | 1.0 |
| Gender | ||||
| Female | 4 (26.7) | 6 (19.4) | Reference | |
| Male | 11 (73.3) | 31 (83.8) | 0.53 (0.13–2.25) | 0.448 |
| Case | ||||
| New case | 4 (26.7) | 13 (32.4) | Reference | |
| Previously treated | 11 (73.3) | 24 (67.6) | 1.49 (0.39–5.63) | 0.747 |
| Resistance category | ||||
| Not XDR# | 6 (40.0) | 18 (35.1) | Reference | |
| XDR# | 9 (53.3) | 19 (45.9) | 1.42 (0.42–4.80) | 0.760 |
| Cavitary | ||||
| No | 0+ (0.0) | 13+ (32.4) | Reference | |
| Yes | 15+ (100.0) | 24+ (67.6) | 17.08 (0.95–308.6) | 0.011 |
| HIV status | ||||
| Negative | 11 (73.3) | 34 (91.9) | Reference | |
| Positive | 4 (26.7) | 3 (8.1) | 4.12 (0.80–21.34) | 0.173 |
| Inactive drugs ¶ | 2 | 1 | 1.92 (1.15–3.21) | 0.012 |
| Age¶ years | 35 | 41 | 0.97 (0.90–1.04) | 0.427 |
Data are presented as n or n (%), unless otherwise stated. Bold type represents statistical significance (p<0.05). XDR: extensively drug resistant. #: World Health Organization classification until 2020, i.e. resistance against one fluoroquinolone and one second-line injectable drug; ¶: median; +: Haldane–Anscombe correction adding 0.5 to each cell to allow calculation of odds ratio.